Development of an efficacious Ara-C-based regimen for the treatment of AML in mice.

<p>Fig. 2A) The survival rate of mice treated with Ara-C at various doses or with 100 µL of PBS control, in accordance with the treatment scheme described in the text. The mice were watched for a period of 50 days. The results shown here are representative of data obtained from 3 separate experiments. Fig. 2B) Histopathological examination of intestine affects Ara-C treatment. Fig. 2C) Treatment protocol for AML mice. The day of infusion of leukemic cells was considered as day 0. Fig. 2D) Suppression of leukemia using the treatment protocol. B6C3F1 mice transplanted with 2×10⁵ B117P cells via tail vein were treated with either Ara-C (n = 12) or PBS (n = 12) as the control. *p<0.05.